Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) / Paragon BioTeck, Bausch Health, Akorn - LARVOL DELTA

POTS Adrenergic Ab (CIHR Aims #1&2) (clinicaltrials.gov) - P=N/A | N=125 | Recruiting | Sponsor: University of Calgary | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular

Vasoactive Drugs in Intensive Care Unit (clinicaltrials.gov) - P4 | N=836 | Recruiting | Sponsor: University of Chicago | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Oct 2026

Trial completion date • Trial primary completion date • Critical care

A Unique Presentation of Ehrlichiosis Causing Neutropenic Fever and Septic Shock with Developing Coagulopathy and Spontaneous Retroperitoneal Bleeding (ASH 2024) - "Her admission was complicated by spontaneous retroperitoneal bleeding and coagulopathy.Case presentation : Patient is a 69-year-old with history of double valve replacement on Coumadin...she continued to spike fevers with worsening neutropenia and leukopenia and was also in Afib with RVR necessitating the use of Neo-Synephrine for vasopressor...Vancomycin and cefepime was discontinued...This organism can also trigger Pancytopenia associated with hypocellular bone marrow.Conclusion : Doxycycline remains the standard treatment for ehrlichiosis, Early administration of doxycycline is crucial in patients with suspicion of tick-borne illnesses to avoid rapid severe progression and increase mortality. Patients with unexplained sepsis despite appropriate treatment, thrombocytopenia and transaminitis with residence in endemic areas, may benefit from empiric doxycycline coverage due to the consequences of delayed treatment of ehrlichiosis."

Anemia • Autoimmune Hemolytic Anemia • Febrile Neutropenia • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Musculoskeletal Pain • Neutropenia • Pain • Septic Shock • Thrombocytopenia • HP

The Utility of the Modified Shock Index (MSI) in Risk Stratification of Patients with STEMI (AHA 2024) - "Vasopressors included norepinephrine, neo-synephrine, and vasopressin while inotropes included milrinone and dobutamine. At our center, an MSI greater than or equal to 0.93 was significantly associated with the use of vasoactive agents, mechanical ventilation and tMCS. An elevated MSI was also associated with prolonged CICU and hospital LOS. MSI is a simple yet informative tool to risk stratify STEMI patients and help determine their initial level of care."

Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Novel Coronavirus Disease • Thrombosis

Satisfaction of Monitored Anesthesia Care (MAC) for Burn Dressing Change Among Patients, Burn Nurse/Techs, and Anesthesia Providers (ASA 2024) - "Neosynephrine was administered for episodes of hypotension. MAC anesthesia can be considered a safe, effective and satisfactory anesthesia technique for burn dressing change with overall good concurrent satisfaction of the patient, burn nurse/tech and anesthesia provider. Applying good communication and effective teamwork can enhance better patient care resulting in good overall satisfaction."

Clinical • Anesthesia • CNS Disorders • Hypotension • Pain • Psychiatry

MAJOR TRAUMA-INDUCED ADULT-ONSET STILL'S DISEASE FLARE RESULTING IN SEVERE SHOCK (CHEST 2024) - "He remained hypotensive despite fluid resuscitation and was admitted to the ICU on neosynephrine drip...He was discharged home on anakinra and a steroid taper... AOSD and other disorders of diffuse systemic inflammation should be considered as potential causes of vasodilatory shock in the ICU, particularly in patients without a clear infectious etiology."

Clinical • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Rheumatology • Septic Shock

Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study (clinicaltrials.gov) - P1 | N=40 | Enrolling by invitation | Sponsor: Yale University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Ischemic stroke

POTS Adrenergic Ab (CIHR Aims #1&2) (clinicaltrials.gov) - P=N/A | N=125 | Recruiting | Sponsor: University of Calgary | Trial primary completion date: Jan 2024 ➔ Dec 2024

Trial primary completion date • Cardiovascular

Streamlined: A Case Study of Organ Donor Optimization (ATC 2024) - "After being transferred to this ORC from an outside hospital the donor was maintained on three pressors (levothyroxine, neosynephrine, and norepinephrine), maintenance fluid, and vasopressin for diabetes insipidus. This case demonstrates that seamless integration of interdisciplinary teams can provide optimal organ function in a brain-dead donor and produce successful outcomes in organ recovery. This streamlined process is evidence that effective communication and preparedness in both the intensive care and perioperative roles yields beneficial outcomes regarding transplant surgery."

Case study • Clinical • Cardiovascular • Critical care • Metabolic Disorders • Transplantation

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Thomas Jefferson University | Trial completion date: Nov 2023 ➔ Oct 2024 | Trial primary completion date: Sep 2023 ➔ May 2024

Surgery • Trial completion date • Trial primary completion date • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

Vasoactive Drugs in Intensive Care Unit (clinicaltrials.gov) - P4 | N=836 | Recruiting | Sponsor: University of Chicago | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Critical care

A HEART BLOCK CONUNDRUM: UNIQUE CASE OF NONISCHEMIC MYOPERICARDITIS AND A TRANSIENT COMPLETE HEART BLOCK (CHEST 2023) - "Patient was placed on a temporary venous pacemaker and put on neo-synephrine drip for blood pressure support...She was started on colchicine, indomethacin and goal directed medical therapy for heart failure with reduced ejection fraction... Although the incidence of heart block with myopericarditis is 1.7%, when a patient presents with complete heart block, it is imperative that nonischemic myopericarditis is treated with goal directed medical therapy rather than permanent pacemaker to avoid cardiac device related complications."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Inflammation • Metabolic Disorders • Obesity • Pain

Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study (clinicaltrials.gov) - P1 | N=40 | Enrolling by invitation | Sponsor: Yale University | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Ischemic stroke

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Thomas Jefferson University | Trial completion date: Jun 2022 ➔ Nov 2023 | Trial primary completion date: Apr 2022 ➔ Sep 2023

Surgery • Trial completion date • Trial primary completion date • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

Sex Differences in Sympathetic Vascular Reactivity at High Altitude (clinicaltrials.gov) - P=N/A | N=17 | Completed | Sponsor: University of Alberta | Enrolling by invitation ➔ Completed | Trial completion date: Nov 2023 ➔ Feb 2023

Trial completion • Trial completion date

Vasoactive Drugs in Intensive Care Unit (clinicaltrials.gov) - P4 | N=836 | Recruiting | Sponsor: University of Chicago | Trial completion date: Dec 2021 ➔ Dec 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Trial completion date • Trial primary completion date • Critical care

Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia. (clinicaltrials.gov) - P=N/A | N=14 | Completed | Sponsor: University of Alberta | Trial completion date: Dec 2020 ➔ Sep 2022 | Trial primary completion date: Dec 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date

Sex Differences in Sympathetic Vascular Reactivity at High Altitude (clinicaltrials.gov) - P=N/A | N=20 | Enrolling by invitation | Sponsor: University of Alberta | Trial primary completion date: Sep 2022 ➔ Feb 2023

Trial primary completion date

Sex Differences in Sympathetic Vascular Reactivity at High Altitude (clinicaltrials.gov) - P=N/A | N=20 | Enrolling by invitation | Sponsor: University of Alberta

New trial

SKey Concepts Surrounding Cardiogenic Shock. (PubMed, Curr Probl Cardiol) - "Future prospective studies and clinical trials may further characterize these phenotypes and apply targeted intervention for each phenotype and SCAI SHOCK stage rather than a one-size-fits-all approach. Overall, there are 8 key concepts of CS; 1) the mortality associated with CS; 2) Shock attributed to AMI may be declining in both incidence and associated mortality; 3) providers should think about hemodynamic, metabolic, inflammation and cardiac function in totality to assess CS; 4) CS is a dynamic process; 5) no randomized trials evaluating use of the PAC in patients with CS; 6) most data supporting neosynephrine as first line agent in CS; 7) most registries suggest that almost half of CS patients do not have any mechanical support, and the vast majority of the remainder utilize the IABP; and 8) patients with AMI CS should receive emergent PCI of the culprit vessel."

Journal • Review • Cardiovascular • Critical care • Immunology • Inflammation

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: University of California, San Francisco | Enrolling by invitation ➔ Completed | Trial completion date: Oct 2022 ➔ Jun 2022 | Trial primary completion date: Oct 2022 ➔ Jun 2022

Trial completion • Trial completion date • Trial primary completion date

Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study (clinicaltrials.gov) - P1 | N=40 | Enrolling by invitation | Sponsor: Yale University | Trial completion date: Dec 2021 ➔ Dec 2023 | Trial primary completion date: Jun 2021 ➔ Jun 2023

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Ischemic stroke

POTS Adrenergic Ab (CIHR Aims #1&2) (clinicaltrials.gov) - P=N/A | N=125 | Recruiting | Sponsor: University of Calgary | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Jan 2022 ➔ Jan 2024

Trial completion date • Trial primary completion date • Cardiovascular

Management Of Elderly Hip Fracture Patient With Multiple Comorbidities Using Neuraxial And Peripheral Nerve Block (ASA 2021) - "The case was completed using femoral nerve block preoperatively which provided adequate pain relief so that the patient could be repositioned for spinal catheter placement. Patient required low dose Neo-Synephrine intraoperatively, but otherwise did well."

Clinical • Anesthesia • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Hypertension • Immunology • Musculoskeletal Diseases • Orthopedics • Pain • Pulmonary Disease • Respiratory Diseases

Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia. (clinicaltrials.gov) - P=N/A; N=14; Completed; Sponsor: University of Alberta

New trial